Immutep Completes Enrollment In TACTI-003 Phase IIb Trial Of Efti And KEYTRUDA In First Line Metastatic Or Recurrent Head And Neck Squamous Cell Carcinoma
Portfolio Pulse from Benzinga Newsdesk
Immutep has completed enrollment in its TACTI-003 Phase IIb trial of Efti and KEYTRUDA for first line metastatic or recurrent head and neck squamous cell carcinoma. The trial is a significant step in the development of these drugs.
November 09, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep's completion of enrollment for its Phase IIb trial of Efti and KEYTRUDA could potentially lead to positive results, which would be beneficial for the company's stock.
The completion of enrollment for a drug trial is a significant milestone in the drug development process. If the trial results are positive, it could lead to the drug's approval and subsequently increase the company's revenues and stock price. However, the results of the trial are still uncertain, hence the confidence score is not at the maximum.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100